Search company, investor...
Bellus Health company logo

Bellus Health

bellushealth.com

Stage

PIPE | IPO

Market Cap

1.52B

About Bellus Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide health solutions. The company's pharmaceutical strategy targets disorders for which there are currently no known cures and limited therapies and includes the development of investigational product candidates for the treatment of Amyloid A amyloidosis Type II diabetes and certain features of metabolic syndrome and Alzheimers disease.

Headquarters Location

275 Armand-Frappier Blvd.

Laval, Quebec, H7V 4A7,

Canada

450-680-4500

Missing: Bellus Health's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bellus Health's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Bellus Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bellus Health is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,898 items

Bellus Health Patents

Bellus Health has filed 1 patent.

The 3 most popular patent topics include:

  • H1 receptor antagonists
  • Piperidines
  • Allergology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/24/2020

6/1/2021

Dosage forms, Drug delivery devices, Prodrugs, Alzheimer's disease, Monoamine oxidase inhibitors

Grant

Application Date

4/24/2020

Grant Date

6/1/2021

Title

Related Topics

Dosage forms, Drug delivery devices, Prodrugs, Alzheimer's disease, Monoamine oxidase inhibitors

Status

Grant

Latest Bellus Health News

Refractory Chronic Cough Therapeutics Market Report (2022 to 2030) - Merck & Co., BELLUS Health Inc, Kyorin Pharmaceuticals, Bayer AG, Shionogi Inc. and Afferent Pharmaceuticals, Inc

Nov 29, 2022

Udaipur, INDIA Pune, Nov. 29, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled, “ Refractory Chronic Cough Therapeutics Market By Drug Class (Neuromodulators, Proton pump inhibitors, and Inhaled Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)- Global Outlook & Forecast 2022-2030" published by Growth Plus Reports, the refractory chronic cough therapeutics market is expected to grow at a CAGR of 3.7% from 2021 to reach US$ 11.99 billion by 2030. Growth Drivers The rising prevalence of refractory chronic cough globally drives the refractory chronic cough therapeutics market. Increased global healthcare spending and disease awareness would increase the market's size, allowing pharmaceutical companies to expand their market share. The medicines in development are centered on cutting-edge methods to treat or ameliorate the illness state. The global refractory chronic cough therapeutics market has been analyzed from three perspectives: drug class, distribution channel, and region. Get a Sample Copy of the Research Report: https://growthplusreports.com/inquiry/request-sample/refractory-chronic-cough-therapeutics-market/7991 Excerpts from ‘By Drug Class Segmentation’ Based on drug class, the global refractory chronic cough therapeutics market is subdivided into: Neuromodulators Inhaled Corticosteroids It has been observed that the neuromodulators segment dominates the global market. Amongst neuromodulators, opioid is the most used drug for the treatment of refractory chronic cough. It can be used to cure mild to moderate symptoms. But due to the side effects associated with the use of opioids, such as an increased risk of fracture, proton pump inhibitors are being increasingly used. Excerpts from ‘By Region Segmentation’ Based on region, the global refractory chronic cough therapeutics market has been segmented into: North America Rest of the World The increasing prevalence of chronic cough in the population and the expansion of products to treat it are the main factors driving the growth of the Asia Pacific refractory chronic cough market. The market expansion is projected to be driven by advancements in the pharmaceutical and biopharmaceutical sectors linked to medications that can treat refractory chronic cough. Additionally, there is an increase in the number of regional startups and international pharmaceutical firms working on chronic cough products. Excerpts from ‘Competitive Landscape’ Merck & Co. Currency Used in the Report RESEARCH METHODOLOGY  Key Players & Competitive Positioning (2021)  MARKET DYNAMICS Neuromodulators Hospital Pharmacies Powered with Complimentary Analyst Hours and Expert Interviews with Each Report Comprehensive quantitative and qualitative insights at segment and sub-segment level Covid 19 impact trends and perspective Granular insights at global/regional/country level Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment Blanket coverage on competitive landscape Winning imperatives

Bellus Health Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bellus Health Rank

Bellus Health Frequently Asked Questions (FAQ)

  • Where is Bellus Health's headquarters?

    Bellus Health's headquarters is located at 275 Armand-Frappier Blvd., Laval.

  • What is Bellus Health's latest funding round?

    Bellus Health's latest funding round is PIPE.

  • Who are the investors of Bellus Health?

    Investors of Bellus Health include OrbiMed Advisors, New Leaf Venture Partners, Apple Tree Partners, Fonds de Solidarite FTQ, Amzak Capital Management and 5 more.

  • Who are Bellus Health's competitors?

    Competitors of Bellus Health include Humanetics, CoImmune, Aegerion Pharmaceuticals, Intarcia Therapeutics, Metabolic Solutions Development and 15 more.

Compare Bellus Health to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

N
Nano-Mite Technologies

Nano-Mite Technologies is engaged in R&D to control obesity using nanotechnology that alters the body's metabolic rate and increase the cell's ability to convert sugar to energy. Per the company, Nano-Mite's technnology could lead to futures in the treatment of traumatic central nervous system damage and neurodegenerative disorders.

O
Osteologix

Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.